US-based specialty pharmaceutical company, pSivida has entered into a funded technology evaluation agreement with an undisclosed pharmaceutical company.
The deal will assess the Durasert technology, pSivida's core technology system, for certain ophthalmology products of the undisclosed pharmaceutical company.
The Durasert technology system is designed to deliver drug quantity to a target site directly into the body for specific duration of time at controlled rates.
pSivida president and CEO Paul Ashton said that the company is transitioning into a specialty pharma company developing its own products, while continually looking for ways to use the company's technology platforms to develop new products.
"Technology agreements such as this enable us work with major companies further expanding our reach and increasing our shots on goal," Ashton added.
